Physician profile

Walid Sayyed

Family Medicine · La Grange, IL

NPI 1508423518

$848.72

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$574.11

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $209.08 2020-2022
Astrazeneca Pharmaceuticals LP $172.04 2023-2024 Farxiga
Lilly USA, LLC $167.40 2024 Zepbound, Mounjaro, Jardiance
Glaxosmithkline, LLC. $118.52 2023 Shingrix, Arexvy
Pfizer INC. $86.06 2021-2024
Boehringer Ingelheim Pharmaceuticals, INC. $30.67 2024 Tradjenta, Synjardy, Jardiance
Genentech, INC. $19.72 2019
Phadia US INC. $17.05 2020
Novo Nordisk INC $15.40 2024
Janssen Pharmaceuticals, INC $12.78 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Walid Sayyed

$848.72

in general payments reported 2019-2025

Years
2019-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/5954331/walid-sayyed

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.